(Total Views: 342)
Posted On: 08/23/2021 10:55:52 AM
Post# of 56

$LXRX News Article - Lexicon's Sotagliflozin Demonstrates Additional Compelling Benefits in Reducing Cardiovascular Endpoints: Results from Soloist and Scored Trials https://marketwirenews.com/news-releases/lexi...35504.html


My Twitter: WhyteStocks